Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2020 | NALIRIFOX as frontline therapy for PDAC

Zev Wainberg • 8 Jul 2020
ESMO WCGIC 2020
Gastrointestinal Cancer Pancreatic Cancer 5-fluorouracil Irinotecan Leucovorin Oxaliplatin

Zev Wainberg, MD, of Ronald Reagan UCLA Medical Center, Los Angeles, CA, discusses primary analysis from a Phase I/II study investigating first-line liposomal irinotecan and 5-fluorouracil/leucovorin and oxaliplatin (NALIRIFOX) in newly diagnosed patients with pancreatic ductal adenocarcinoma (PDAC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Zev Wainberg

0:43
daNIS-2: NIS793 with nab-paclitaxel and gemcitabine in mPDAC
Zev Wainberg • 20 Jan 2023
0:32
DKN-01 with bevacizumab and chemotherapy in advanced CRC
Zev Wainberg • 20 Jan 2023
0:54
NAPOLI-3: first-line NALIRIFOX in metastatic pancreatic ductal adenocarcinoma
Zev Wainberg • 20 Jan 2023
0:48
Current and future directions in gastric cancer research
Zev Wainberg • 12 Apr 2022

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals